Overview
Clinical phenotype terms— hover any for plain English:
FDA & Trial Timeline
4 eventsHospices Civils de Lyon — NA
Biocodex — PHASE3
treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableRivfloza
RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 m…
RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m2
Oxlumo
treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Rare Disease Specialist
Treatment Centers
8 centersClinical Trial Site
📍 Phoenix, Arizona
Stanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🏥 NORDBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
Financial Resources
2 resourcesTravel Grants
No travel grants are currently matched to Primary hyperoxaluria type 1.
Community
No community posts yet. Be the first to share your experience with Primary hyperoxaluria type 1.
Start the conversation →Latest news about Primary hyperoxaluria type 1
Disease timeline:
New recruiting trial: Oxalate Excretion Profile in Patients with a Heterozygous Mutation of the AGXT (alanine-glyoxylate Aminotransferase) Gene
A new clinical trial is recruiting patients for Primary hyperoxaluria type 1
New trial: Long Term Extension Study in Patients With Primary Hyperoxaluria
Phase PHASE3 trial recruiting. DCR-PHXC
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Primary hyperoxaluria type 1
Are there clinical trials for Primary hyperoxaluria type 1?
Yes — 1 recruiting clinical trial is currently listed for Primary hyperoxaluria type 1 on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Primary hyperoxaluria type 1?
18 specialists and care centers treating Primary hyperoxaluria type 1 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Primary hyperoxaluria type 1?
2 patient support programs are currently tracked on UniteRare for Primary hyperoxaluria type 1. See the treatments and support programs sections for copay assistance, eligibility, and contact details.